Pfizer, Inc. (PFE)

NASDAQHealthcare

$25.66
+$0.12 (+0.5%)

January 21, 2026 at 19:15 UTC

Interactive Chart
PFE
1H
3H
6H
12H
1D
1W
1M
3M
6M
12M (YTD)
2Y
5Y
All
About Pfizer, Inc.

Name

Pfizer, Inc.

CEO

Albert Bourla

Industry

Healthcare

Year Founded

1849

Employees

81,000

Pfizer, Inc. is a pharmaceutical company that discovers, develops, and supplies medicines and vaccines used in clinical practice worldwide. The operating model links science with delivery: research feeds trials, approvals lead to scaled production, and medical education supports appropriate use. Manufacturing and quality systems favor continuity, so once therapies enter practice, supply stays steady. Field teams focus on safety, labeling clarity, and guidance that fits real workflows in hospitals and clinics. Access programs and country teams adapt to local rules while holding to common standards. The goal is simple and long-term: turn evidence into dependable options that clinicians can trust and patients can live with. Within healthcare, Pfizer’s role is to make new treatments feel workable in daily care.

Analyst Ratings
Consensus Recommendation
Analyst consensus: 13 Buy, 7 Hold, 1 Sell
Buy13
Hold7
Sell1
Fundamentals & Financials
Revenue (TTM)
$62.7B
Net Income (TTM)
$9.8B
EPS (TTM)
$1.73
ROA (TTM)
4.71%
Current Ratio
1.28
Dividend Yield
0.1%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement (Quarterly)
ItemQ3 2025
Revenue$16,654M
Cost of Sales$4,172M
Gross Profit$12,482M
Operating Income$3,550M
Net Income$3,541M
EPS$0.62
Technical Indicators

Pfizer, Inc.'s Technical Indicators Summary

Pfizer’s current price sits comfortably above its short and long-term moving averages, reflecting a solid upward trend supported by multiple buy signals from both the 10- and 200-day averages. Momentum indicators such as the CCI and MACD confirm positive momentum, although the RSI and Williams %R suggest a more cautious hold stance. The ADX indicates a moderate trend strength, while the average true range points to stable volatility without significant spikes. Despite this bullish environment, the On-Balance Volume shows a sell signal, highlighting some divergence in volume trends. Overall, the technical picture for Pfizer remains constructive, with price action supported by strong moving averages and momentum indicators.

Buy
13 signals
Neutral
7 signals
Sell
1 signal
Overall: Bullish62% Bullish signals
IndicatorValue
RSI (14)
55.28
Stochastic %K (14, 3, 3)
74.29
CCI (20)
153.37
WPR (14)
-30.51
Momentum (10)
0.47
MFI
60.15
MACD Level (12, 26)
0.08
Bollinger Bands
$24.71 - $25.76
ATR (14)
$0.49 (1.93%)
ADX (14)
20.18
OBV
709,593,300
Simple Moving Averages
$24.47 - $25.42(5 indicators)
Exponential Moving Averages
$24.92 - $25.46(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

The bell brought only a slight negative bias, with PFE edging -0.196% lower to open at 25.47 versus 25.52. The sector opens with a modest gain of 1.24%, offering a light tailwind for PFE. Pfizer stock dips slightly amid sector gains as the company invests in oncology and GLP-1 drugs to boost growth.

Price Change

from $25.52 close

+$0

Trading Volume

Below avg (50.1M)

8.3M

vs S&P 500 Today

Underperforming Market

-0.86%

52-Week Position

Upper range

67.9%

Updated: January 21, 2026 at 15:45 UTC

Quote Summary
OpenPrevious Close
$25.47$25.52
Day Range52 Week Range
$25.38 - $25.78$20.92 - $27.69
VolumeAvg. Volume
22.6M64.5M
Market CapP/E Ratio
$146B14.9